Over a span of 35 years, Pamela Hay has worked for numerous biopharma companies, initially in positions as in-house legal and business positions of increasing responsibility. As a founding partner of Red Sky Partners, she then spent 15 years as a management consultant focused on interim C-level roles and strategic advisory and business assignments.
Prior to her recent retirement as a partner at Red Sky, Pamela’s consulting assignments included numerous interim executive roles and strategic assignments to biotech/biopharma companies to support periods of transition and growth. These assignments involved companies and projects spanning the start-up through Phase 3 product development stages in multiple therapeutic indications and modalities. In these roles, she often led the planning, diligence process and negotiation of partnering, licensing and M&A transactions. Her assignments have included serving as founding CEO for Sight Stream (formerly Kera Therapeutics), interim CBO for Ribon Therapeutics, co-CEO of Harbour Antibodies (where she led its sale to Harbour Biomed), and business strategy and development roles for Redona (formerly 28-7), Nimbus Therapeutics, Merrimack Pharma, Ribometrix, Almirall, Cardurion and Luc Therapeutics.
Previously, Pamela was Chief Commercial Officer of Domantis Ltd, a Cambridge UK biotech company focused on single domain antibody technology where she led partnerships with Abbvie and BMS prior to its sale to GSK for $450m in 2007. She was SVP, Corporate Development at Dyax Corp, where she designed and implemented the company’s broad-based licensing and partnering programs for antibody and peptide phage display IP and technology, resulting in over 75 business deals. Her earlier positions include General Counsel of T Cell Sciences and Corporate Attorney at Biogen.
Pamela has a BA in Biology from Cornell University’s School of Arts and Sciences, and a JD from the University of Wisconsin School of Law.